Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
10.13
-0.39 (-3.71%)
Sep 29, 2026, 11:23 AM EDT - Market open
Pharming Group Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Pharming Group stock has a consensus rating of "Strong Buy" and an average price target of $34.35. The average 1-year stock price forecast is 239.09% higher than the current stock price, while the lowest is $23.4 (+131.00%) and the highest is $39 (+285.00%).
Price Target: $34.35 (+239.09%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Pharming Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $38 | Buy | Reiterates | $38 | +275.12% | Sep 23, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $37 | Buy | Reiterates | $37 | +265.25% | Sep 22, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $41 → $40 | Buy | Maintains | $41 → $40 | +294.87% | May 8, 2026 |
Financial Forecast
Revenue This Year
383.35M
from 376.13M
Increased by 1.92%
Revenue Next Year
417.27M
from 383.35M
Increased by 8.85%
EPS This Year
0.03
from 0.00
Increased by 681.00%
EPS Next Year
0.03
from 0.03
Decreased by -10.40%
EPS and Forward PE are based on non-GAAP adjusted numbers.